David Domzalski

CIK 1727794 · PRESIDENT AND CEO · last filed 2026-06-02

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$284.5K

Companies

3

Total Filings

66

Lifetime Open-Market Net

-$10.3K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
VYNE PRESIDENT AND CEO 438,779 $0.65 $284.5K $103.6K 40 2026-06-02
VYNE Therapeutics Inc. (MNLO) Delisted President and CEO 1,240,966 $0 5 2020-07-02
Foamix Pharmaceuticals Ltd. (FOMX) Delisted CEO 324,028 -$113.9K 20 2020-03-03

Recent Filings · Page 3 of 7

66 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2023-04-04 VYNE Tax (F) −2,734 -$8.4K EDGAR
2023-01-04 VYNE Tax (F) −10,685 -$1.6K EDGAR
2022-12-02 VYNE Grant (A) +34,705 $6.9K EDGAR
2022-10-04 VYNE Tax (F) −10,683 -$2.4K EDGAR
2022-07-05 VYNE Tax (F) −10,683 -$4.2K EDGAR
2022-06-02 VYNE Grant (A) +11,887 $4.1K EDGAR
2022-04-04 VYNE Tax (F) −23,186 -$15.1K EDGAR
2022-03-18 VYNE Grant (A) +312,302 $0 EDGAR
2022-01-04 VYNE Tax (F) −6,887 -$7.0K EDGAR
2021-12-02 VYNE Grant (A) +4,705 $4.1K EDGAR
Showing 2130 of 66
Page 3 of 7
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.